Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (60%) |
| §112 only | 2 (20%) |
| No statute on record | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 43.9% | +26.4% |
| LEE, CHIHYI NMN | 1 | 32.5% | +62.8% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 63.5% | +38.8% |
| CHICKS, ASHLI ARIANA | 1 | 64.1% | +44.9% |
| HAVLIN, ROBERT H | 1 | 52.3% | +27.2% |
| DAHLIN, HEATHER RAQUEL | 1 | 46.5% | +48.9% |
| O'BRIEN, LEA S | 1 | 50.0% | +8.3% |
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.4% |
| MCMILLIAN, KARA RENITA | 1 | 30.6% | +37.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 147d overdue |
| 18037523 | DEUTERIUM-MODIFIED THIENOPYRIDONE COMPOUND | HAVLIN, ROBERT H | 138d overdue |
| 17922336 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | DAHLIN, HEATHER RAQUEL | 103d overdue |
| 17603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | MCMILLIAN, KARA RENITA | 30d overdue |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 24d overdue |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | BRISTOL, LYNN ANNE | 24d overdue |
| 18275142 | BISPECIFIC ANTIBODY | NICKOL, GARY B | 7d |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 14d |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1629 | 2 |
| 1626 | 2 |
| 1628 | 1 |
| 1646 | 1 |
| 1613 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275142 | BISPECIFIC ANTIBODY | NICKOL, GARY B | 1643 | §103 | Non-Final OA | 7d | Pending | Jul 31, 2023 |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 1628 | §103 | Non-Final OA | 24d overdue | Pending | Jul 27, 2023 |
| 18268818 | SALT FORM OF TETRA-SUBSTITUTED OLEFIN COMPOUND, CRYSTAL, AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §112 | Final Rejection | 77d | Pending | Jun 21, 2023 |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 1626 | §103 | Non-Final OA | 147d overdue | Pending | May 22, 2023 |
| 18037523 | DEUTERIUM-MODIFIED THIENOPYRIDONE COMPOUND | HAVLIN, ROBERT H | 1626 | §103 | Non-Final OA | 138d overdue | Pending | May 17, 2023 |
| 17922336 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | Other | Non-Final OA | 103d overdue | Pending | May 01, 2023 |
| 18020584 | SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA | O'BRIEN, LEA S | 1646 | Other | Non-Final OA | 4d overdue | Pending | Feb 09, 2023 |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | 24d overdue | Pending | Oct 28, 2022 |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 1613 | §103 | Non-Final OA | 14d | Pending | Jul 12, 2022 |
| 17603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | MCMILLIAN, KARA RENITA | 1623 | §103 | Non-Final OA | 30d overdue | Pending | Oct 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial